> ## Content Index
> Fetch the complete content index at: https://busy-cuscus.pikapod.net/llms.txt
> Use this file to discover other available public pages before exploring further.

# How Does a New Drug Get Approved and Funded in Canada?
- URL: https://busy-cuscus.pikapod.net/how-does-a-new-drug-get-approved-and-funded-in-canada/
- Published: 2026-10-21T04:54:34.000Z
- Updated: 2026-10-24T03:45:25.000Z
- Description: The four steps a new drug goes through in Canada — Health Canada review, funding assessment, price negotiations, and coverage decisions — and why approval doesn't mean coverage.
- Author: Christopher Cutler
- Tags: Drug Access

## The short answer

Before a new drug can be **approved and publicly funded** in Canada, it passes through four separate steps:

1. **Health Canada review** — is the drug safe and effective enough to be sold here?
2. **Public-funding assessment** — is it good value for public money?
3. **Price negotiations** — what will public plans pay for it?
4. **Coverage decisions** — each public drug plan decides whether to fund it, and for whom.

**Approval and coverage are separate decisions**, made by different organizations, on different timelines. A drug can clear step 1 and still take years to reach step 4 — and some never do. The timing and order of these steps can vary, and some steps may happen at the same time.

| Step                          | Who decides                                        | What they decide                      | Typical time                                                                                 |
| ----------------------------- | -------------------------------------------------- | ------------------------------------- | -------------------------------------------------------------------------------------------- |
| 1\. Health Canada review      | Health Canada                                      | Can the drug be sold in Canada?       | 300-day target (180 days for priority review)                                                |
| 2\. Public-funding assessment | Canada's Drug Agency (INESSS in Quebec)            | Is it good value for public money?    | New target: 180 days (streamlined process, 2026); recent median 206 days                     |
| 3\. Price negotiations        | pan-Canadian Pharmaceutical Alliance (pCPA)        | What will public plans pay?           | Roughly 4 months to decide to negotiate, plus 4–5 months at the table                        |
| 4\. Coverage decisions        | Each provincial, territorial and federal drug plan | Will this plan fund it, and for whom? | Months per plan; about two years on average from approval to funding for recent cancer drugs |

  
This page explains each step in plain English, using daraxonrasib — a new pancreatic cancer drug approved in the United States in August 2026 — as the running example.

## Step 1: Health Canada review

![Outdoor Government of Canada sign reading Health Canada, 100 Eglantine Driveway](https://busy-cuscus.pikapod.net/content/images/2026/10/IMG_1355.jpeg)

**Who:** Health Canada, the federal department that regulates drugs. Health Canada is the body that approves prescription drugs for sale in Canada — its [drugs and health products portal](https://www.canada.ca/en/health-canada/services/drugs-health-products.html?ref=busy-cuscus.pikapod.net) is where authorizations are published.

**What happens:** The manufacturer submits evidence, and Health Canada assesses safety, effectiveness and manufacturing quality before deciding whether to authorize sale. If the answer is yes, the drug receives a Notice of Compliance and a Drug Identification Number (DIN), and it can legally be sold in Canada.

**How long it takes:** Health Canada's target is **300 days** for a standard review. Drugs for serious or life-threatening conditions with few existing treatments can get **priority review**, with a target of **180 days**. Reviews can run longer if Health Canada asks the manufacturer for more information. (Source: Health Canada's priority review policy and published service standards.)

**What this step does *not* do:** It does not decide who pays. Approval means a drug *can* be sold in Canada — full stop. Everything about funding happens in the steps that follow.

## Step 2: Public-funding assessment

**Who:** [Canada's Drug Agency](https://www.cda-amc.ca/?ref=busy-cuscus.pikapod.net), formerly CADTH — and in Quebec, [INESSS](https://www.inesss.qc.ca/?ref=busy-cuscus.pikapod.net).

**What happens:** Canada's Drug Agency reviews clinical benefits and value for money and makes a funding recommendation. Quebec uses INESSS. This work can overlap with Health Canada's review — a manufacturer can start this process before Health Canada has finished, so the two clocks often run at the same time.

The recommendation is advice to the public drug plans, not a decision. It comes in three broad flavours: fund it, don't fund it, or fund it **with conditions** — for example, only for certain patients, or only if the price comes down. In practice, almost every positive recommendation carries conditions.

**How long it takes:** The review itself has recently taken a median of about **seven months** (206 days across recommendations issued in 2024, per Canada's Drug Agency review data). In 2026, the agency introduced a streamlined process that targets a final recommendation in **180 days**. The longer view was slower: a median of 221 days across 2020 to 2024.

## Step 3: Price negotiations

**Who:** The [pan-Canadian Pharmaceutical Alliance, or pCPA](https://www.pcpa.ca/?ref=busy-cuscus.pikapod.net) — the provinces, territories and federal government negotiating together — across the table from the manufacturer.

**What happens:** The pCPA may negotiate pricing and other terms with the manufacturer for participating public drug plans. One national negotiation replaces thirteen separate ones, and the agreed price is confidential. (A separate federal board, the [Patented Medicine Prices Review Board (PMPRB)](https://www.pmprb-cepmb.gc.ca/?ref=busy-cuscus.pikapod.net), also caps the maximum price that can be charged for a patented drug in Canada, whether or not the pCPA is involved.)

If negotiations succeed, the pCPA issues a letter of intent and each plan can move to list the drug. If they fail, public funding usually stops there.

**How long it takes:** There is no fixed deadline, and this step is the least predictable. Recent data puts the median at roughly **four months for the pCPA just to decide whether to negotiate**, and another **four to five months** at the table. A newer fast lane — the Early Negotiation Process, built for cancer drugs reviewed internationally under Project Orbis — is designed to start talks earlier and conclude within 65 business days once they begin.

## Step 4: Coverage decisions

**Who:** Each individual public drug plan — every province and territory, plus federal plans for populations like veterans and First Nations.

**What happens:** Individual public plans decide whether to fund the drug and who qualifies. Even after a successful national negotiation, each plan signs its own listing agreement and sets its own rules — often "special authorization," meaning your care team has to show you meet specific criteria before the plan pays. Coverage does not necessarily begin everywhere at once: one province may list a drug months before another, and a small number of negotiated drugs are never listed by some plans at all.

**How long it takes:** Months per plan, and it varies. Across all four steps, studies of recent cancer drugs have found it takes **about two years on average from Health Canada approval to public funding** — roughly double the wait in comparable countries.

![Infographic 'The Path to a New Drug in Canada' shows four steps: Health Canada review, funding assessment, pricing, coverage.](https://busy-cuscus.pikapod.net/content/images/2026/10/IMG_1368.webp)

## So where is daraxonrasib in this process?

Daraxonrasib (brand name Rasonque) is a pill that targets RAS mutations, which drive the overwhelming majority of pancreatic cancers. In its phase 3 trial, patients lived a median of about 13 months, versus about 7 months on standard chemotherapy. Because the drug only works against RAS-driven cancers, knowing a tumour's mutation status matters — that starts with [biomarker testing](https://busy-cuscus.pikapod.net/testing/). We track the drug's Canadian status step by step on our [daraxonrasib in Canada](https://busy-cuscus.pikapod.net/is-daraxonrasib-available-in-canada/) page.

- **United States:** Approved by the FDA on August 26, 2026 — the first targeted therapy approved for metastatic pancreatic cancer. Its FDA review ran under [**Project Orbis**](https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis?ref=busy-cuscus.pikapod.net), an international program where regulators review a drug together. Health Canada took part in that review as a collaborator.
- **Europe:** The EMA's expert committee recommended approval on October 15, 2026; the final European Commission decision is still pending.
- **Canada:** As of October 2026, there is **no public Health Canada decision yet**, and no public timeline. In pathway terms, daraxonrasib is at **step 1** — and because Health Canada participated in the Orbis review, there is reason to hope the Canadian review can move faster than a cold start. Whether a Canadian submission has even been filed is the first question to answer, and it is one of the questions the foundation is asking the manufacturer directly.

Until steps 1 through 4 are complete, Canadian access routes are the early ones: clinical trials, Health Canada's Special Access Programme (which lets a doctor request an unauthorized drug for a specific patient, if the manufacturer agrees to supply it), or — after Canadian approval but before public funding — private insurance, which sometimes covers drugs public plans have not listed yet.

## Frequently asked questions

**Who approves prescription drugs in Canada?** Health Canada. Its review (step 1) decides whether a drug can be sold in Canada at all. Approving a drug for sale is separate from funding it — that decision belongs to the public drug plans, at the end of steps 2 through 4.

**Does Health Canada approval mean my province will pay for the drug?** No. Approval (step 1) only means the drug can be sold in Canada. Public funding requires the assessment, price negotiation and listing steps that follow — and each province decides for itself.

**How long does the whole process take?** Health Canada's review targets 300 days (180 for priority review). After approval, public funding takes about two years on average for recent cancer drugs, though the steps overlap and timelines vary widely from drug to drug.

**Who decides what a new drug costs in Canada?** The manufacturer sets an initial price, capped by the federal Patented Medicine Prices Review Board. The price public plans actually pay is negotiated confidentially by the pCPA.

**Why does Quebec have its own assessment?** Quebec runs its funding assessments through INESSS instead of Canada's Drug Agency, so Quebec's recommendation — and sometimes its timeline — is separate. Quebec still takes part in pCPA price negotiations.

**Can I get a drug before it is publicly funded?** Sometimes. Options include clinical trials, the Special Access Programme for unauthorized drugs (your doctor applies; the manufacturer must agree), private insurance after Health Canada approval, and manufacturer patient-support programs. Your oncology team can tell you which routes fit your situation.

---

*This page explains a process; it is not medical advice. For questions about your own treatment options, talk to your oncology team. Sources: Health Canada (priority review policy and service standards); Canada's Drug Agency review data, 2020–2024 recommendations; pCPA negotiation timelines; C.D. Howe Institute analysis of the pCPA's accelerated negotiation pathways; Revolution Medicines, RASolute 302 trial results.*